Nanchong Psychosomatic Hospital, Nanchong, 637700, China.
Pharmacogenomics. 2020 Jul;21(11):761-770. doi: 10.2217/pgs-2020-0050. Epub 2020 Jun 29.
The purpose of this study was to evaluate the clinical utility of pharmacogenetic (PGx) testing in the treatment of bipolar disorder in the Chinese population. Compare efficacy and side effects, measured by the Clinical Global Impression Efficacy Index scale (CGI-EI), of PGx-guided treatment (n = 100) to that of the traditional treatment (n = 100). Compared with the traditional treatment, PGx-guided treatment reduced the number of medications used for patients, also achieving better efficacy at 4, 8 and 12 weeks. In the analysis of side effects, the PGx-guided group significantly reduced the side effects. Our study suggests that PGx testing results-guided treatment is superior to the traditional treatment of bipolar disorder in the Chinese population.
本研究旨在评估药物遗传学（PGx）检测在治疗中国人群双相情感障碍中的临床应用价值。通过临床总体印象疗效指数量表（CGI-EI）比较 PGx 指导治疗（n=100）与传统治疗（n=100）的疗效和副作用。与传统治疗相比，PGx 指导治疗减少了患者使用的药物数量，并且在第 4、8 和 12 周时疗效更好。在副作用分析中，PGx 指导组显著降低了副作用。本研究表明，PGx 检测结果指导治疗在治疗中国人群双相情感障碍方面优于传统治疗。
